Infertility refers to the inability to conceive after a year of unprotected intercourse between a sexually active, non-contracepting couple. It affects approximately 15% of reproductive-aged couples worldwide. Infertility drugs can boost fertility in patients with certain health conditions causing infertility symptoms by regulating hormonal imbalances and stimulating ovulation. They are used extensively during Assisted Reproductive Technologies (ART) like In-Vitro Fertilization (IVF) to increase the success rate of the procedures. Common infertility drug classes include Gonadotropins, Clomiphene Citrate, Aromatase Inhibitors, and others. These drugs when taken as prescribed under medical guidance, can help induce ovulation, increase sperm count, treat polycystic ovarian syndrome and other conditions
causing infertility.
The global Infertility Drugs Market is estimated to be valued at US$ 3699 million in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends observed in the infertility drugs market is the rising preference for fertility tourism. Fertility tourism refers to travelling to other countries seeking assisted reproductive treatment like IVF. This is mainly attributed to long waiting periods, higher success rates, and relatively lower cost of treatment in developing countries compared to developed nations. According to the National Conference of State Legislatures, over 20,000 U.S. residents travel to foreign countries each year for fertility treatments. A study by PMCL Health estimates that over 60,000 Americans traveled abroad for fertility treatments in 2020 alone. This rising cross-border fertility treatment seeking is expected to continue driving the demand for infertility drugs globally over the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate in this market due to the high cost of R&D that is required to develop new and effective infertility drugs. Bargaining power of buyers: The bargaining power of buyers is high given the presence of many established players providing a variety of treatment options. Bargaining power of suppliers: Suppliers have moderate bargaining power given the availability of raw material suppliers globally. Threat of new substitutes: Threat from new substitutes is low as there are limited treatment alternatives available for infertility currently. Competitive rivalry: The competitive rivalry in the market is high due to the presence of many large and small players competing for market share.
Key Takeaways
The Global Infertility Drugs Market Size is expected to witness high growth over the forecast period.
North America is the largest as well as the most promising regional market for infertility drugs. In North America, the US holds the major market share owing to advanced healthcare facilities and greater adoption of fertility treatments at an early age in the country.
Key players operating in the infertility drugs market are Merck, Ferring Pharmaceuticals, MSD, AbbVie Inc., LIVZON, Zydus Cadila, and Sun Pharmaceutical Industries Ltd. Merck is one of the leading players in the infertility drugs market with its portfolio including fertility medications like Cetrotide and Gonal-f. In October 2022, the company launched Imyject, a prefilled autoinjector for Letrozole, in the US for ovulation stimulation in infertility treatment.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
